Aflibercept

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4287 publications

Comparison of adverse events of three anti-VEGF drugs for the treatment of age-related macular degeneration.

Comparison of adverse events of three anti-VEGF drugs for the treatment of age-related macular degeneration.

Journal: The Malaysian journal of pathology

Published: August 31, 2026

Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease.

Initial Impact of Loss of Copay Assistance From a National Nonprofit Fund on Outcomes of Retinal Disease.

Journal: Journal of vitreoretinal diseases

Published: August 26, 2026

Prognostic Factors for Clinical Outcomes and Lesion Reactivation in Stage 2-3 Type 3 Macular Neovascularization Treated Using a Treat-and-Extend Regimen.

Prognostic Factors for Clinical Outcomes and Lesion Reactivation in Stage 2-3 Type 3 Macular Neovascularization Treated Using a Treat-and-Extend Regimen.

Journal: Retina (Philadelphia, Pa.)

Published: August 25, 2026

Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10.

Incidence and associations of Retinal pigment epithelial (RPE) tear post-loading phase of aflibercept 2mg in Treatment Naïve Neovascular Age-Related Macular Degeneration (nAMD): PRECISE study report 10.

Journal: Retina (Philadelphia, Pa.)

Published: August 25, 2026

Early visual response provides additional prognostic value beyond baseline OCT features in diabetic macular edema.

Early visual response provides additional prognostic value beyond baseline OCT features in diabetic macular edema.

Journal: European journal of ophthalmology

Published: August 22, 2026

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data.

Real-world retinal vasculitis events reported with FDA-approved intravitreal anti-VEGF and complement inhibitor agents: an analysis of FAERS data.

Journal: Retina (Philadelphia, Pa.)

Published: August 21, 2026

Correction: Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis.

Correction: Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis.

Journal: Ophthalmology and therapy

Published: August 20, 2026

Functional and Anatomic Outcomes at 12 Months After Switching to Faricimab in Treatment-Recalcitrant Neovascular Age-Related Macular Degeneration.

Functional and Anatomic Outcomes at 12 Months After Switching to Faricimab in Treatment-Recalcitrant Neovascular Age-Related Macular Degeneration.

Journal: Journal of vitreoretinal diseases

Published: August 20, 2026

Association Between Anti-vascular Endothelial Growth Factor Therapy Exposure and Visual Outcomes in Diabetic Macular Edema and Retinal Vein Occlusion.

Association Between Anti-vascular Endothelial Growth Factor Therapy Exposure and Visual Outcomes in Diabetic Macular Edema and Retinal Vein Occlusion.

Journal: Journal of visualized experiments : JoVE

Published: August 18, 2026

OCT as a Dynamic Biomarker in Retinal Disease Management: Evidence, Decision Strategies, and Clinical Guidance for OCT Decision-Point Use.

OCT as a Dynamic Biomarker in Retinal Disease Management: Evidence, Decision Strategies, and Clinical Guidance for OCT Decision-Point Use.

Journal: Journal of vitreoretinal diseases

Published: July 31, 2026

AI-assisted OCT biomarker quantification reveals distinct retinal fluid trajectories in central retinal vein occlusion.

AI-assisted OCT biomarker quantification reveals distinct retinal fluid trajectories in central retinal vein occlusion.

Journal: Retina (Philadelphia, Pa.)

Published: July 28, 2026

Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study.

Short-term intraocular pressure changes following intravitreal injections of aflibercept 8mg versus 2mg: A prospective comparative study.

Journal: European journal of ophthalmology

Published: July 27, 2026

Showing 1-12 of 4,287

Last Updated: 09/19/2026